Document is current
Any future updates will be listed below
-
Authors
Ezra, Daniel G. https://orcid.org/0000-0002-3565-1167
Azumi, Atsushi
Briceño, César A. https://orcid.org/0000-0001-5301-0630
Rajaii, Fatemeh https://orcid.org/0000-0002-1012-2293
Salvi, Mario https://orcid.org/0000-0002-0276-0367
Sales-Sanz, Marco https://orcid.org/0000-0002-8757-2946
Brockwell, Laura
Idowu, Oluwatobi O. https://orcid.org/0000-0003-3269-5719
-
Funding
Funding for this research was provided by:
F. Hoffmann‑La Roche Ltd. (Basel, Switzerland) provided financial support for the preparation, review, and approval of the manuscript.
- License Information
-
More Information
Article History
Received: 29 October 2025
Accepted: 23 December 2025
First Online: 16 February 2026
Declarations
:
: Not required.
: Not required.
: Not required.
: D.G.E. is a consultant for Calilia. A.A. is a consultant for Amgen, Chugai, and Roche, and is a principal investigator for trials for Chugai, Immunovant, and Roche. C.A.B. is a consultant for Amgen, argenx and Roche/Genentech, Inc. and his academic activities are partially funded by an unrestricted grant from Research to Prevent Blindness. F.R. is a consultant for Acelyrin, Amgen, and Khartis, and is a principal investigator for trials for Immunovant, Roche, and Viridian. M.S. is a consultant and advisory board member for Amgen, argenx, IBSA, Immunovant, Lycia, Merck, Roche, Third Rock Ventures, Tourmaline, and Viridian. M.S.-S. is a consultant for Amgen and Immunovant, and is a principal investigator for trials for Amgen, argenx, Immunovant, Roche, Sling, and Viridian. L.B. is an employee of and holds stocks or stock options in Roche Products Ltd. O.O.I. is an employee of and holds stocks or stock options in Genentech, Inc.
